for non-cystic fibrosis bronchiectasis
FDA approved Brinsupri as the first targeted therapy for non-CF bronchiectasis, addressing a population of ~350,000 US patients previously managed with macrolide antibiotics and supportive care.
Bronchiectasis is a lung disease in which the airways become permanently widened and damaged, causing chronic cough with mucus, shortness of breath, chest pain, and frequent lung infections. Brinsupri is an oral medicine that blocks DPP-1, an enzyme immune cells use to switch on the destructive proteins that drive airway inflammation. By calming that inflammatory cascade, it may reduce the flare-ups that repeatedly damage already-weakened airways.
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Source: ClinicalTrials.gov